脓毒症或脓毒性休克成人中β-内酰胺类抗生素延长输注与间歇输注的比较:系统评价与Meta分析
该系统评价与Meta分析纳入18项随机临床试验、共9108例脓毒症或脓毒性休克危重成人(中位年龄54岁,IQR 48-57;男性5961例[65%]),比较β-内酰胺类抗生素延长输注(持续或延长)与间歇输注。主要结局为90天全因死亡率,17项试验(9014例)提供数据,汇总风险比RR 0.86(95%可信区间0.72-0.98;I²=21.5%;高确定性),延长输注与90天死亡率降低相关的后验概率为99.1%。延长输注还与ICU死亡率降低相关(RR 0.84;95%CI 0.70-0.97;高确定性),并增加临床治愈(RR 1.16;95%CI 1.07-1.31;中等确定性)。作者结论认为当前证据具有高度确定性,临床医生可考虑将延长输注作为脓毒症和脓毒性休克管理的标准治疗。
要点
- 在ICU脓毒症或脓毒性休克成人中,延长输注β-内酰胺类抗生素与间歇输注相比,90天全因死亡率汇总RR为0.86(95%CI 0.72-0.98;I²=21.5%;高确定性),延长输注与死亡率降低相关的后验概率为99.1%。
- 延长输注与ICU死亡率降低相关(RR 0.84;95%CI 0.70-0.97;高确定性),与临床治愈增加相关(RR 1.16;95%CI 1.07-1.31;中等确定性)。
- 证据基于18项随机临床试验、9108例脓毒症或脓毒性休克危重成人(中位年龄54岁,IQR 48-57;男性5961例[65%]),主要结局分析纳入17项试验(9014例)。
- 作者结论认为当前证据具有高度确定性,临床医生可考虑将延长输注作为脓毒症和脓毒性休克管理的标准治疗。
- 检索数据源包括MEDLINE(通过PubMed)、CINAHL、Embase、Cochrane对照试验中心注册库(CENTRAL)和ClinicalTrials.gov,检索时间自建库至2024年5月2日。
适用人群与场景
- ICU脓毒症或脓毒性休克危重成人(18项试验共9108例;中位年龄54岁,IQR 48-57;男性5961例[65%])。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入18项比较β-内酰胺类抗生素延长输注(持续或延长)与间歇输注的随机临床试验,共9108例脓毒症或脓毒性休克危重成人(中位年龄54岁,IQR 48-57;男性5961例[65%])。
- 主要结局:90天全因死亡率,17项试验(9014例)提供数据,延长输注 vs 间歇输注的汇总RR为0.86(95%可信区间0.72-0.98;I²=21.5%;高确定性),延长输注与90天死亡率降低相关的后验概率为99.1%。
- 次要结局:ICU死亡率降低(RR 0.84;95%可信区间0.70-0.97;高确定性);临床治愈增加(RR 1.16;95%可信区间1.07-1.31;中等确定性)。
- 证据合成采用贝叶斯框架为主要分析方法,频率学框架为次要方法;采用GRADE方法评估证据确定性;数据提取和偏倚风险评估由2名评价者独立完成。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(18项随机临床试验)。
- 证据确定性:90天全因死亡率高确定性;ICU死亡率高确定性;临床治愈中等确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,当前证据具有高度确定性,临床医生可考虑将延长输注β-内酰胺类抗生素作为脓毒症和脓毒性休克管理的标准治疗。
- 在ICU脓毒症或脓毒性休克成人中,与间歇输注相比,延长输注β-内酰胺类抗生素与90天死亡率降低相关(RR 0.86;95%CI 0.72-0.98),可考虑用于此类患者。
指南或共识出处
- PROSPERO注册号:CRD42023399434。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There is uncertainty about whether prolonged infusions of β-lactam antibiotics improve clinically important outcomes in critically ill adults with sepsis or septic shock.
OBJECTIVE: To determine whether prolonged β-lactam antibiotic infusions are associated with a reduced risk of death in critically ill adults with sepsis or septic shock compared with intermittent infusions.
DATA SOURCES: The primary search was conducted with MEDLINE (via PubMed), CINAHL, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from inception to May 2, 2024.
STUDY SELECTION: Randomized clinical trials comparing prolonged (continuous or extended) and intermittent infusions of β-lactam antibiotics in critically ill adults with sepsis or septic shock.
DATA EXTRACTION AND SYNTHESIS: Data extraction and risk of bias were assessed independently by 2 reviewers. Certainty of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. A bayesian framework was used as the primary analysis approach and a frequentist framework as the secondary approach.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause 90-day mortality. Secondary outcomes included intensive care unit (ICU) mortality and clinical cure.
RESULTS: From 18 eligible randomized clinical trials that included 9108 critically ill adults with sepsis or septic shock (median age, 54 years; IQR, 48-57; 5961 men [65%]), 17 trials (9014 participants) contributed data to the primary outcome. The pooled estimated risk ratio for all-cause 90-day mortality for prolonged infusions of β-lactam antibiotics compared with intermittent infusions was 0.86 (95% credible interval, 0.72-0.98; I2 = 21.5%; high certainty), with a 99.1% posterior probability that prolonged infusions were associated with lower 90-day mortality. Prolonged infusion of β-lactam antibiotics was associated with a reduced risk of intensive care unit mortality (risk ratio, 0.84; 95% credible interval, 0.70-0.97; high certainty) and an increase in clinical cure (risk ratio, 1.16; 95% credible interval, 1.07-1.31; moderate certainty).
CONCLUSIONS AND RELEVANCE: Among adults in the intensive care unit who had sepsis or septic shock, the use of prolonged β-lactam antibiotic infusions was associated with a reduced risk of 90-day mortality compared with intermittent infusions. The current evidence presents a high degree of certainty for clinicians to consider prolonged infusions as a standard of care in the management of sepsis and septic shock.
TRIAL REGISTRATION: PROSPERO Identifier: CRD42023399434.
参考来源
- Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA. 2024. PMID: 38864162. doi:10.1001/jama.2024.9803
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。